Delcath Systems Q2 Earnings Call Highlights

3 weeks ago 11

MarketBeat

Thu, August 6, 2026 astatine 11:04 AM CDT 6 min read

Key Points

Interested successful Delcath Systems, Inc.? Here are 5 stocks we similar better.
Revenue and outlook improved: Second-quarter gross roseate 20% twelvemonth implicit twelvemonth to $29.1 million, driven by a 30% summation successful HEPZATO KIT volume. Delcath raised its 2026 gross guidance to $104 million–$108 cardinal and expects affirmative adjusted EBITDA.
Commercial enlargement continued: Delcath ended the 4th with 31 progressive attraction centers and remains connected way to scope astir 37 by year-end. New diligent starts and backup REMS-certified teams are intended to enactment capableness and attraction volume.
Pipeline improvement is advancing but faces enrollment challenges: Phase II trials successful metastatic colorectal and HER2-negative bosom crab are underway, portion the institution evaluates further indications. Delcath said enrollment has been slower than expected due to the fact that of coordination and grooming requirements astatine attraction centers.

Delcath Systems (NASDAQ:DCTH) reported second-quarter 2026 gross of $29.1 million, up from $24.2 cardinal a twelvemonth earlier, arsenic maturation successful HEPZATO KIT income supported continued commercialized enlargement and concern successful objective programs beyond metastatic uveal melanoma.

HEPZATO KIT gross totaled $27.1 million, which Chief Executive Officer Gerard Michel said was 21% higher than the comparable 2025 play contempt the instauration of 340B pricing successful July 2025. Chief Financial Officer Sandra Pennell said HEPZATO measurement accrued 17% sequentially from the archetypal 4th and 30% twelvemonth implicit year.

→ SpaceX's First Earnings Report Could Decide Whether Shorts oregon Bulls Have Control

The institution reported nett income of $2.7 million, unchanged from the prior-year quarter. Adjusted EBITDA was $7.6 million, compared with $9.8 cardinal successful the 2nd 4th of 2025. Delcath ended the 4th with $95.9 cardinal successful currency and investments and generated $5.7 cardinal successful operating currency flow.

Raised Revenue Outlook

Delcath accrued its full-year 2026 gross guidance to a scope of $104 cardinal to $108 million. Pennell said the updated outlook reflects first-half performance, peculiarly the gait of caller diligent starts, arsenic good arsenic a much humble assumed seasonal diminution successful the 2nd half.

→ 3 Drone Stocks That Should Soar After the Summer Slump

The forecast implies astatine slightest 28% maturation successful HEPZATO KIT measurement from 2025, according to the company. Delcath besides expects full-year gross borderline of 86% to 89% and affirmative adjusted EBITDA.

Second-quarter gross borderline was 90%, compared with 86% a twelvemonth earlier. Pennell attributed the betterment to amended overhead absorption, favorable manufacturing show and higher HEPZATO volume. She said the institution remains blimpish connected the full-year borderline outlook due to the fact that of imaginable further manufacturing costs.

Read Entire Article